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Translational relevance 47 
Active immunotherapy represents a promising anticancer strategy aiming to trigger specific T-48 
cell responses against tumor cells to avoid disease relapse or progression. However, the 49 
enhancement of clinical efficacy depends on strong in vivo T-cell activation, which requires 50 
optimization of vaccine formulations with powerful antigens and adjuvants. In this clinical trial, 51 
we tested a vaccine formulation consisting of Montanide, IMP321/LAG-3Ig, and five tumor-52 
associated antigens/peptides. Montanide is clinically graded Incomplete Freund’s Adjuvant with 53 
very good depot effects. IMP321 is a non-TLR agonist with interesting adjuvant properties. The 54 
five peptides were chosen to elicit a broad spectrum of cytotoxic CD8 T-cells and a helper CD4 55 
T-cell response. All components have a favorable safety profile. Serial vaccinations induced 56 
tumor-specific T-cells responses in all 16 vaccinated melanoma patients, encouraging further 57 
development of this approach, e.g. in combination with checkpoint blockade. 58 
  59 
4 
 
Abstract 60 
Purpose: Cancer vaccines aim to generate and maintain anti-tumor immune responses. We 61 
designed a phase I/IIa clinical trial to test a vaccine formulation composed of Montanide ISA-51 62 
(Incomplete Freund’s Adjuvant), LAG-3Ig (IMP321, a non-Toll like Receptor agonist with 63 
adjuvant properties) and five synthetic peptides derived from tumor-associated antigens (four 64 
short 9/10-mers targeting CD8 T-cells, and one longer 15-mer targeting CD4 T-cells). Primary 65 
endpoints were safety and T-cell responses. 66 
Experimental design: Sixteen metastatic melanoma patients received serial vaccinations. Up to 67 
9 injections were subcutaneously administered in 3 cycles, each with 3 vaccinations every 3 68 
weeks, with 6-14 weeks interval between cycles. Blood samples were collected at baseline, one 69 
week after the 3rd, 6th and 9th vaccination, and 6 months after the last vaccination. Circulating T-70 
cells were monitored by tetramer staining directly ex vivo, and by combinatorial tetramer and 71 
cytokine staining on in vitro stimulated cells. 72 
Results: Side effects were mild to moderate, comparable to vaccines with Montanide alone. 73 
Specific CD8 T-cell responses to at least one peptide formulated in the vaccine preparation 74 
were found in 13 of 16 patients. However, two of the four short peptides of the vaccine 75 
formulation did not elicit CD8 T-cell responses. Specific CD4 T-cell responses were found in all 76 
16 patients.  77 
Data interpretation: We conclude that vaccination with IMP321 is a promising and safe strategy 78 
for inducing sustained immune responses, encouraging further development for cancer 79 
vaccines as components of combination therapies. 80 
  81 
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Introduction 82 
Melanoma is a highly aggressive cancer, with increasing incidence and mortality rates. While 83 
surgery can cure melanoma detected at early stages, the prognosis of most patients with 84 
metastatic disease is unfavorable. Chemotherapy, irradiation and therapy with IFN-α are of 85 
limited efficacy (1, 2). Recently, much more effective therapies have been developed, with the 86 
introduction of BRAF inhibitors active for patients whose tumor expresses V600 mutations in the 87 
BRAF gene (3). High-dose Interleukin 2 (IL-2) was showing marked successes but with 88 
considerable side effects and costs, and only for selected patients (4). More recently, a novel 89 
and more widely applicable form of immunotherapy has been introduced: a “checkpoint 90 
blockade”, consisting of a monoclonal antibody specific for CTLA-4 (Cytotoxic T-Lymphocyte-91 
Associated protein 4), named Ipilimumab. It was approved in 2011 for the treatment of 92 
metastatic melanoma (5). Subsequently, antibodies that block PD-1/PD-L1 (Programmed Death 93 
1/ Programmed Death-Ligand 1) pathway have been introduced and shown great progress in 94 
the treatment of metastatic melanoma (6) leading to the first market approvals in 2014. Of high 95 
interest, positive clinical studies are also reported in patients with carcinomas of lung, kidney, 96 
bladder and head & neck, and large efforts with current studies are also ongoing in patients with 97 
other cancers. Besides CTLA-4 and PD-1/PD-L1, the targeting of further inhibitory lymphocyte 98 
receptors (“checkpoints”) is explored in an increasing number of pre-clinical studies (7, 8). One 99 
of these is LAG-3 (Lymphocyte Activation Gene-3 or CD223), an inhibitory receptor that 100 
modulates T-cell homeostasis, proliferation and activation (9). The LAG-3-specific antibody 101 
BMS986016 is already in clinical development, with two clinical trials recruiting patients with 102 
solid tumors or hematologic neoplasms, respectively (www.clinicaltrials.gov). 103 
Therapeutic vaccination is a promising strategy against malignant diseases. Similar as for other 104 
immunotherapies, a major challenge is to break immune tolerance, to induce a powerful and 105 
targeted immune response, and to avoid autoimmune side effects. Over the last decades major 106 
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efforts were made to develop immunomodulatory molecules that act as vaccine adjuvants. An 107 
important class of innate immune receptors, the Toll-like Receptors (TLRs) are targeted and 108 
studied in animals and in humans, uncovering novel means of inducing strong immune 109 
responses (10). Beside TLRs, there are additional receptors for activating innate immune 110 
pathways, such as RIG-I-like receptors, NOD-like receptors, AIM2-like receptors, and STING 111 
(11). While these receptors are interesting for future vaccine development, this field is less 112 
advanced than targeting TLRs. 113 
Since several years, the non-TLR agonist, soluble LAG-3Ig (IMP321, Immutep S.A., France) is 114 
in clinical development (12, 13). The rational is at least two-fold. First, this molecule can block 115 
inhibitory signals in T-cells similar to the “checkpoint blockade” principle. Second, it can 116 
stimulate Antigen-Presenting Cells (APCs), which makes LAG-3Ig an attractive vaccine 117 
adjuvant. LAG-3 is a CD4-like protein able to bind to MHC (Major Histocompatibility Complex) 118 
class II molecules with a 100-fold higher affinity than CD4. IMP321 is one of a few clinical-grade 119 
non-TLR adjuvants for T-cell vaccination. LAG-3Ig stimulates the innate immune system by 120 
inducing activation and migration of APCs, particularly dendritic cells. Consequently, it 121 
enhances specific immune responses, by stimulation of antigen cross presentation to CD8 T-122 
cells, and by decreasing regulatory T-cells frequency and function (9). Clinical trials with IMP321 123 
showed already promising results when used as adjuvant for vaccination against hepatitis B and 124 
influenza viruses in healthy individuals (14, 15). Several trials have provided evidence for 125 
clinical activity in patients with advanced renal cell carcinoma, metastatic breast carcinoma and 126 
metastatic melanoma (16-18). 127 
Antigens used in cancer vaccines should be exclusively expressed by the tumor cells, or should 128 
be lineage specific in case of tumors arising from non-vital tissues/cells such as melanoma. The 129 
melanocyte differentiation antigen MART-1 (Melanoma Antigen Recognized by T-cells-1)/ 130 
Melan-A is one of the rare antigens that are expressed by a vast majority of patient’s tumors 131 
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(19, 20). Often, this antigen triggers T-cell responses upon tumor progression, which can be 132 
amplified by immunotherapy (21-24). Furthermore, cancer-testis antigens such as Mage-A3 133 
(Melanoma-associated antigen 3) and NY-ESO-1 are excellent antigens, due to their high 134 
degree of tumor specificity, the relatively high affinity of peptides derived from these antigens 135 
that bind to HLA (Human Leukocyte Antigen)-A*0201 and presentation to specific CD8 T-cells. 136 
NA-17 represents also a promising target antigen for the development of melanoma 137 
immunotherapy as it triggers tumor-specific CD8 T-cells and showed promising clinical 138 
responses in a dendritic cell-based vaccine trial (25). Importantly, simultaneous targeting of 139 
multiple antigens likely reduces the risk of tumor outgrowth by escape variants. 140 
Besides components that trigger innate immune cells and antigen specific ones, vaccines may 141 
also be enhanced by delivery systems with depot effect. One of the best adjuvants for T-cell 142 
vaccines is Incomplete Freund’s Adjuvant (IFA), produced as Montanide ISA-51 (Seppic, 143 
France). Due to its non-resorbable mineral oil component, it persists at subcutaneous injection 144 
sites for several weeks up to multiple months and contributes to continuous or repetitive T-cell 145 
stimulation. 146 
Based on the above outlined evidence and on our own previous experience (18), we designed a 147 
vaccine formulation composed of IMP321 (LAG-3Ig), Montanide ISA-51 (IFA) and tumor 148 
antigen-specific peptides. We combined four short HLA-A2 restricted peptides (Melan-A, NY-149 
ESO-1, Mage-A3 and NA-17) to target CD8 T-cells, and one longer 15-mer peptide (Mage-A3), 150 
containing HLA class II epitopes to target CD4 T-cells. Sixteen metastatic melanoma patients 151 
were included in this study and vaccinated up to 9 times. 152 
For comprehensive immune monitoring we developed a combinatorial tetramer staining allowing 153 
parallel quantification of 13 specific CD8 T-cell populations in T-cell cultures after one 154 
stimulation in vitro. In addition, Melan-A-specific CD8 T-cells were quantified directly ex vivo, 155 
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without any culture steps. Finally, we quantified the frequency and evaluated the functional 156 
potential of Mage-A3-specific CD4 T-cells induced by vaccination. 157 
The vaccinations were well tolerated, showing comparable (mostly local) adverse events like 158 
vaccination with Montanide alone. Remarkably, the vaccines induced specific CD4 T-cell 159 
responses in all 16 vaccinated melanoma patients (100%), and specific CD8 T-cells to at least 160 
one antigen formulated in the vaccine in 13 patients (81%). 161 
  162 
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Patients, Materials and Methods 163 
More details are shown in the Supplementary Materials and Methods section. 164 
Patients, vaccination and blood samples 165 
HLA-A2+ patients with histologically confirmed metastatic melanoma of stage III to IV, 166 
expressing Melan-A/MART-1 (determined by Reverse Transcription (RT)-PCR or 167 
immunohistochemistry) were included upon informed consent, in this phase I/IIa, single center, 168 
open, non comparative study. The primary objective was measurement of antigen-specific 169 
immune responses besides safety and tolerability assessments. Local ethic review committees 170 
and responsible health authorities approved the study, which was carried out according to the 171 
Good Clinical Practice guidelines and the Declaration of Helsinki and was registered at 172 
www.clinicaltrials.gov (NCT01308294). 173 
Eligible patients were immunized subcutaneously with the synthetic peptides and 250 µg 174 
IMP321/LAG-3Ig (Immutep S.A., France). The first 6 vaccines were formulated with 1 mL 175 
Montanide ISA-51 (Seppic Inc, France), the last 3 vaccines without Montanide. Patients with an 176 
expected survival of at least 3 months (status at entry is described in Supplementary Table 177 
S1A) received 9 vaccines scheduled in 3 cycles with 3 vaccinations (3 weeks intervals between 178 
vaccines, 6 to 14 weeks between cycles), based on observations that multiple boosters can not 179 
only induce but also maintain T-cell responses during many months or even years (26, 27). The 180 
clinical-grade peptides used in the vaccines were: Melan-A26-35 native EAAGIGILTV or analog 181 
(A27L) ELAGIGILTV, NY-ESO-1157-165 SLLMWITQC, Mage-A3112-120 KVAELVHFL, NA17 182 
VLPDVFIRC, all representing known class I HLA-A2 peptides; and Mage-A3243-258 183 
KKLLTQHFVQENYLEY, containing a class II HLA-DP4 epitope. Blood samples were collected 184 
before the first vaccine (C0), one week after the third vaccination of each cycle (C1, C2, C3), 185 
and 6 months after the end of the third cycle (follow up : FU) for some patients. Peripheral Blood 186 
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Mononuclear Cells (PBMCs) were isolated by density gradient using Lymphoprep (Axis-Shieldy) 187 
and immediately cryopreserved in RPMI1640 supplemented with 40% FCS (Fetal Calf Serum) 188 
and 10% DMSO (dimethyl sulfoxide). 189 
In Vitro Stimulation (IVS) of T-cells with specific peptides 190 
CD8+ T-cells or CD4+ T-cells were enriched using MACS (Magnetic Activated Cell Sorting) 191 
technology (Miltenyi Biotec). The negative fraction of cells was loaded with laboratory-grade 192 
peptides (listed in Supplementary Table S2), irradiated (30 Gray) and used as APCs to 193 
stimulate peptide-specific T-cells during 10 or 12 days in presence of IL-2. 194 
Flow cytometry: quantification of specific T-cells by tetramer staining 195 
Freshly thawed cells or cultured cells were stained using similar protocols. As a first step, single 196 
tetramer staining or combinatorial tetramer staining (TCMetrix, Lausanne, Switzerland) was 197 
performed. Cells were incubated 45 minutes at room temperature with class I tetramers 198 
(combinatorial tetramers or tetramer Melan-A-PE) or 60 minutes at 37°C with class II tetramer 199 
(tetramer Mage-A3/DP4-PE). The combinatorial tetramers are listed in Supplementary Table 200 
S2. In addition, surface antibodies and dead cell exclusion marker were used to identify live 201 
CD4 and CD8 T-cells. Data were acquired on a Gallios Flow Cytometer (Beckman Coulter) and 202 
analyzed using FlowJo 7.6.5 software (TreeStar). 203 
Mage-A3-specific CD4 T-cell clones, cell sorting and stimulation 204 
A blood sample from patient Lau1187 (collected after 3 vaccines; C1) was stimulated with 205 
Mage-A3243-258 peptide for 16 days, as described above in IVS section. CD4+ tetramer-low and 206 
CD4+ tetramer-high cells were separately cloned. The specificity of each clone was checked by 207 
tetramer staining analyzed by flow cytometry (BD FACS Array). 12 days after expansion, clones 208 
were phenotyped in separate tubes for their expression level of CD4, T-Cell Receptor (TCR) 209 
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and for their tetramer brightness. In parallel, clones were stimulated with 0,5 and 5 µg/mL Mage-210 
A3243-258 peptide in presence of Brefeldin A 10 µg/mL for 6 hours. Intracellular Cytokine Staining 211 
(ICS) was performed as described in the Supplementary Materials and Methods section. 212 
Analysis of cytokine co-expression was done with SPICE software version 5.2. Finally, clones 213 
were clonotyped as previously described (28). 214 
Statistics 215 
Student’s t-test (two-sample two-tailed comparison) or paired t-test was used for statistical 216 
calculations. P < 0.05 was considered significant (* = p < 0.05; ** = p < 0.01; *** = p < 0.001; **** 217 
= p < 0.0001; ns = not significant).  218 
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Results 219 
Favorable safety profile 220 
In this study, sixteen HLA-A2+ patients with metastatic melanoma received serial vaccines (up 221 
to 9 vaccines; see Supplementary Table S1A). The vaccines contained IMP321, Montanide and 222 
four short peptides representing class I epitopes presented by HLA-A2, and one long 15-mer 223 
peptide containing a class II epitope presented by HLA-DP4. 224 
The patient’s baseline characteristics are shown in Supplementary Table S1A. There were 8 225 
women and 8 men, with an age ranging from 21 to 84 years. Ten patients had stage III 226 
melanoma and 6 patients with stage IV melanoma at study entry. 14 patients finished the entire 227 
clinical trial protocol and 2 patients discontinued the study earlier due to disease progression. 228 
The safety analysis of the treatment showed a comparable severity of side-effects commonly 229 
reported for cancer vaccines. The 16 patients experienced in total 588 adverse events. One 230 
event was of life-threatening severity and was qualified as serious adverse event as it involved 231 
hospitalization of the patient, but it was not related to the study treatment. Twelve events were 232 
of severe intensity, all caused by melanoma metastases and considered as not related to the 233 
study treatment. The majority (534 events, i.e. 91%) of all adverse events were of mild intensity. 234 
Supplementary Table S1B shows all adverse events with an incidence of more than 5, 235 
according to their severity and their relationship to the study treatment. A total of 135 injections 236 
were applied to 16 patients, reported adverse events were mainly expected/prelisted local 237 
reactions at vaccine injection sites (313 events, i.e. 53.2%), consisting of induration (100 238 
events), erythema (83 events), pain (72 events), warmth (38 events), and injection site 239 
reactivation (20 events). They were mostly mild and were resolved rapidly except indurations 240 
that could last for several weeks. Indeed, Montanide ISA-51 is well known to form a depot 241 
allowing long-term local vaccine persistence and causing local inflammation. The systemic 242 
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reactions reported during study corresponded to 113 events of all adverse events (19.2%). The 243 
ones that were considered as possibly or probably related to the study treatment were mainly of 244 
mild severity. The most frequent systemic events were headache, myalgia, chills, asthenia and 245 
arthralgia. Tumor progression was the only type of grade 3 adverse event. No grade 4 adverse 246 
events related to the study treatment were observed. 247 
All together, the combination of IMP321, Montanide and 5 peptides was safe and well tolerated, 248 
with mild severity local adverse events, no cases of ulcerations at the vaccine injection sites, 249 
and no treatment related systemic adverse events higher than grade 2. 250 
Quantification of specific CD8 T-cells by combinatorial tetramer staining after IVS 251 
To obtain maximal information on specific CD8 T-cells with a minimum of blood volume, we 252 
chose to use combinatorial tetramer staining. This technique is based on the combination of 253 
multiple tetramers labeled with a combination of multiple dyes (29, 30), allowing the detection of 254 
multiple specific T-cell populations in the same sample (up to 15 specificities with 4 dyes). We 255 
set up a panel detecting 13 specificities allowing the quantification of 13 populations of virus and 256 
tumor-specific CD8 T-cells in 10 million PBMCs (see the list of specificities in Supplementary 257 
Table S2). 258 
As a first step, we expanded the T-cells by IVS with peptides in 2 conditions, one with viral 259 
antigens (Epstein-Barr Virus (EBV), Influenza (Flu), Cytomegalovirus (CMV), Human 260 
Immunodeficiency Virus (HIV)) and the other one with tumor antigens; some of which 261 
corresponded to the antigens included in the vaccinations (Melan-A, NY-ESO-1, Mage-A3, 262 
NA17), and others not (“control” tumor antigens, namely Meloe-1 (Melanoma-overexpressed 263 
antigen-1), Gp100-2 (Glycoprotein 100-2), Meloe-2, Mage-A10, Tyrosinase). In addition, to 264 
avoid competition of the well-growing specificities versus the less frequent (weaker-growing) 265 
ones, we split the cells in 2 to 12 independent cultures (96 wells) depending on the quantity of 266 
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CD8 T-cells we purified. After 12 days of culture, the frequencies of specific CD8 T-cells were 267 
quantified by combinatorial tetramer staining, determined using the gating strategy shown in 268 
Supplementary Fig. S1. 269 
The majority of patients had antigen-specific T-cells for EBV, Flu and/or Melan-A (13 to 15 270 
patients of 16; detection limit at 0.1%; Fig. 1A and Supplementary Table S3). Furthermore, 2/3 271 
of the patients had detectable amounts of CMV and/or NY-ESO-1-specific CD8 T-cells; 1/3 272 
Meloe-1, Gp100-2 and/or Meloe-2-specific cells. Mage-A10 or Tyrosinase-specific T-cells were 273 
only detected in 1 patient (Lau 616 and Lau 1366, respectively). None of them had HIV, Mage-274 
A3 or NA17-specific CD8 T-cells above the detection limit, despite that the patients had been 275 
vaccinated with the two latter peptides. HIV was a reliable negative control, based on the 276 
negative HIV serology result available for each patient. 277 
In addition, EBV, Flu, CMV and Melan-A-specific CD8 T-cells were found in more than 80% of 278 
the cultures (Fig. 1A and 1B), and the frequencies of specific cells were mainly above 10% of 279 
the cells (Fig. 1B). NY-ESO-1 specific CD8 T-cells were found in 34% of culture wells, and 280 
Meloe-1, Gp100-2 and Meloe-2-specific CD8 T-cells maximally in 13% of cultures. For these 281 
specificities, the frequencies mainly ranged between 0.1 to 1%. Mage-A10-specific CD8 T-cells 282 
were at high frequency in one patient (Lau 616) who had previously been vaccinated with this 283 
peptide, with different adjuvants (31). 284 
For further analysis of the impact of vaccination on antigen-specific CD8 T-cells, we focused on 285 
the specificities found in more than one patient, and calculated mean frequencies in positive 286 
culture wells, excluding wells with frequencies below the detection limit of 0.1%. Thus, we 287 
focused on EBV, Flu and CMV for the control viral antigens; on Melan-A and NY-ESO-1 for the 288 
tumor antigens against which the patients were vaccinated; and on Meloe-1, Gp100-2 and 289 
Meloe-2 for the remaining tumor antigens. 290 
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We were able to detect Melan-A and/or NY-ESO-1-specific CD8 T-cells in 15 and 9 patients, 291 
respectively. Overall, we found no significant increase of the frequencies of Melan-A-specific 292 
CD8 T-cells after vaccination when analyzed after IVS, but a significant increase was found for 293 
NY-ESO-1-specific CD8 T-cells (Fig. 2A-C). However, it is well known that IVS with peptide 294 
efficiently amplifies previously primed and thus highly frequent Melan-A-specific T-cells, leading 295 
to the saturation of this kind of proliferation system. Therefore, we analyzed the frequency 296 
changes with vaccination on Melan-A-specific cells after excluding the 3 patients who showed 297 
high frequencies already at baseline, due to tumor priming or previous treatment (C0 > 15%). In 298 
the remaining 12 patients, we found a significant increase of Melan-A-specific CD8 T-cells 299 
following vaccination (Fig. 2D). 300 
Concerning the tumor antigen specificities not included in the vaccine (Meloe-1, Meloe-2 and 301 
Gp100-2) and the viral antigens (EBV, Flu, and CMV), we did not observe any significant 302 
frequency changes (Supplementary Fig. S2). 303 
Together, the IVS-combinatorial tetramer technique showed increased frequencies of circulating 304 
CD8 T-cells (corresponding to an increase of 2-fold or more as compared to baseline) to at least 305 
one of the 4 class I peptides administered, in 13 of 16 metastatic melanoma patients. 306 
Direct ex vivo quantification of circulating Melan-A-specific CD8 T-cells 307 
In the majority of vaccine studies in cancer patients, IVS is required to allow the detection of 308 
tumor antigen-specific T-cells, as their in vivo frequencies are below the detection limits (which 309 
is approximately 0.01% of CD8 T-cells for flow cytometry-based techniques). Detection and 310 
analysis of tumor-specific T-cells directly ex vivo is still a major challenge. Yet, we and others 311 
were able to detect, in blood samples, Melan-A-specific CD8 T-cells, directly ex vivo, without 312 
any culture step, as these cells are unusually frequent. Moreover, some vaccine components 313 
such as CpG-B are capable of inducing extraordinarily strong expansion of human CD8 T-cells 314 
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(32). We monitored the frequencies of Melan-A-specific CD8 T-cells before and after each 315 
vaccination cycle, directly ex vivo (Fig. 3 and Supplementary Table S4). Six patients showed an 316 
increase of 2-fold or more in their frequencies of Melan-A-specific CD8 T-cells after vaccination 317 
(Supplementary Table S4). Overall, this approach allowed revealing that the frequencies of 318 
Melan-A-specific T-cells increased significantly after vaccination (Fig. 3A). Remarkably, data 319 
obtained from frequencies of Melan-A-specific CD8 T-cells as determined by the IVS-320 
combinatorial tetramer technique strongly correlated (p < 0.0001) to those collected after direct 321 
ex vivo analysis with standard tetramers (Fig. 3B). 322 
All together, our data demonstrate that vaccination with IMP321, Montanide and short peptides 323 
induced significant expansion of tumor-specific CD8 T-cells in vivo. 324 
Induction of Mage-A3-specific CD4 T-cells in all 16 vaccinated patients 325 
In addition to the short peptides, one longer peptide (a 15-mer) derived of the Mage-A3 protein 326 
was used for vaccination, with the aim to activate tumor-specific CD4 T-cells. For immunological 327 
monitoring, we stimulated PBMC in vitro with the peptide for 10 days, followed by challenging 328 
the cells with the Mage-A3243-258 peptide for 4 hours, allowing the quantification of IFN-γ and 329 
TNF-α positive cells upon ICS (Fig. 4A and 4B). Remarkably, the frequencies of IFN-γ and TNF-330 
α producing cells were always increased after vaccination, demonstrating that all 16 patients 331 
uniformly generated CD4 T-cell responses with at least 2-fold higher frequencies as compared 332 
to baseline (C0). 333 
Patients had been included in the study irrespective of their HLA class II genes. Previous 334 
publications reported that the Mage-A3243-258 peptide can be presented by HLA-DP4 and HLA-335 
DQ6 (33, 34). Using blocking antibodies specific for HLA-DP, HLA-DQ or HLA-DR, we found a 336 
dominant usage of HLA-DP (Fig. 4C). As 13 of the patients were HLA-DP*0401 and/or HLA-337 
DP*0402 (Supplementary Table S1A), we synthesized a class II tetramer to quantify Mage-338 
17 
 
A3/DP4-specific CD4 T-cells (Fig. 4D). Indeed, the frequencies of Mage-A3/DP4-specific CD4 339 
T-cells were increased in all HLA-DP4+ melanoma patients, with an expansion of 2-fold or 340 
higher, including patient Lau 616 who was not typed for HLA class II. 341 
In contrast to the first 6 vaccines, Montanide ISA-51 was omitted for the last 3 vaccines, with the 342 
aim to reduce local toxicities, and to determine whether this strategy may nevertheless achieve 343 
the desired booster effects. Despite slight trends towards reduced frequencies of some of the T-344 
cell populations analyzed after cycle 3 as opposed to the previous two cycles, there were no 345 
statistically significant differences, suggesting that booster vaccinations without Montanide are a 346 
valuable option. 347 
Characterization of two distinct Mage-A3-specific CD4 T-cell populations identified in 348 
patient Lau 1187 349 
While analyzing the Mage-A3-specific CD4 T-cells, we observed 2 populations of specific cells 350 
with different tetramer staining intensities in patient Lau 1187 (Fig. 5A), which we sorted and 351 
cloned separately. Each clone showed a tetramer-low (described thereafter as Low) or tetramer-352 
high (High) staining, corresponding to the tetramer staining intensity before sorting (Fig. 5A). 353 
First, we checked the tetramer staining characteristics after expansion of the two clonal families 354 
and confirmed that the tetramer-high and tetramer-low profiles (Fig. 5B) were stable over time 355 
(data not shown). Theoretically, higher intensity tetramer staining could be associated to a 356 
higher expression at the surface level of the TCR and/or the co-receptor (CD4), and/or to a 357 
higher TCR avidity (35, 36). We next measured the expression level of TCR and CD4 358 
separately, in order to avoid competition of the staining antibodies. As shown in Fig. 5B, a 359 
higher tetramer staining was not associated with a higher TCR or CD4 staining. We further 360 
tested the functionality of the clones in a 6 hour-peptide stimulation assay, and quantified 361 
cytokines by ICS (Fig. 5C). We found that the 2 families of clones differed in their cytokine 362 
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profile (Fig. 5C), with tetramer-high clones producing more TNF-α, IL-2, and also the Th2 363 
cytokine IL-13, but the same amounts or less of the Th1 cytokine IFN-γ than tetramer-low 364 
clones (Fig. 5C). Tetramer-high clones were also more polyfunctional than tetramer-low clones 365 
(Fig. 5D). 366 
Sequencing of the CDR3β (Complementarity Determining Region 3β) region of the TCR 367 
revealed that all the tetramer-low clones were of the same clonotype (VB6, CDR3β 368 
SIGLAGGTDTQ, JB2.3), whereas all the tetramer-high clones came from a second clonotype 369 
(VB7, CDR3β SRGTLPPMNTEA, JB1.1). These data suggest that each of the two clonal 370 
populations originated from a single precursor. 371 
 372 
Clinical Results 373 
Although it was not in the focus of the study, we documented the clinical results. Twelve of the 374 
16 patients entered the study without detectable tumor, due to previous surgical resection. Ten 375 
of these 12 patients remained tumor-free throughout the entire study period, whereas 2 patients 376 
developed new metastases, causing 1 patient to stop after the second cycle of vaccination. The 377 
remaining 4 patients entered the study with detectable metastases and all had disease 378 
progression. Of those, 1 patient stopped study participation after the first vaccination cycle. At 379 
the end of the vaccination period, all patients were alive. Subsequently, two of the 16 patients 380 
died after 8 and 14 months, respectively. The median follow up time was 47.2 months (with a 381 
range from 35.9 months to 57.3 months) at the time of analyses (July 8th, 2015). After the study, 382 
9 of the 16 patients received one or more additional anti-melanoma treatments, which were 383 
surgery (7 patients), chemotherapy (3 patients), irradiation (3 patients), BRAF inhibitors (3 384 
patients, 2 of which were the 2 deceased patients) and anti-CTLA-4 antibody followed by anti-385 
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PD-1 antibody (1 patient). Obviously, post-study treatments may impact on the clinical outcome 386 
in an uncontrolled manner, a caveat inherent to most clinical trials. 387 
  388 
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Discussion 389 
In this phase I/IIa study, 16 metastatic melanoma patients were vaccinated with IMP321 (LAG-390 
3Ig), Montanide ISA-51 (IFA), and five synthetic peptides, resulting in CD4 and CD8 T-cell 391 
responses that were antigen specific, as no effect was seen on T-cells specific for other 392 
antigens than those used for vaccination (summarized in Table 1). 393 
The treatment was well tolerated; none of the patients discontinued the study due to treatment 394 
related adverse events. Montanide ISA-51 has been used in a large number of cancer patients, 395 
and in cumulative doses up to 16 mL (37). Despite the overall favorable safety profile of 396 
Montanide ISA-51, the local side effects can be strong and may require surgical removal of the 397 
non-resorbed material when causing persistent local inflammation with ulceration leading to 398 
bacterial infections (38). This was however not encountered in this study; the maximal local 399 
toxicity was grade 2. 400 
The safety and toxicity profile of IMP321 has been established in two randomized phase I trials 401 
of subcutaneous vaccination against Influenza virus (Flu, n=60) and the Hepatitis virus (HBsAg, 402 
n=48) in healthy volunteers (14, 15). Both studies revealed very good clinical tolerability with a 403 
low toxicity profile for the four dose levels of IMP321: 3, 10, 30 and 100 μg. 404 
The vaccinations induced specific CD8 T-cell responses to at least one of the injected antigens 405 
in 13 of 16 melanoma patients (81%), and specific CD4 T-cell responses in all patients (16/16, 406 
100%). Thus, the vaccine fulfilled the intended purpose to simultaneously induce CD8 and CD4 407 
T-cell responses, according to the principle that CD8 cytotoxic T-cells are key players in the 408 
control and the killing of tumor cells, and CD4 T-cell help supports the CD8 T-cell responses 409 
(39, 40). We detected Melan-A and NY-ESO-1-specific CD8 T-cells in the majority of patients 410 
(15/16 and 9/16 patients, respectively). Among them, 10 patients showed an increase in the 411 
frequency of Melan-A-specific cells and 8 patients in the frequency of NY-ESO-1-specific cells 412 
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(Fig. 2 and Table 1). Unfortunately, we did not find CD8 T-cell responses to Mage-A3 and 413 
NA17. Although difficult to explain, it may be possible that the applied vaccine formulation has 414 
weakness for activating T-cells with low precursor frequencies, a problem that is also observed 415 
with other types of vaccines (26, 27, 41). 416 
Remarkably, all 16 patients developed Mage-A3-specific CD4 T-cell responses, independently 417 
of their HLA class II genotypes. The Mage-A3243-258 peptide is presented by HLA-DP4 and HLA-418 
DQ6 (33, 34). Among the 16 patients, 13 were HLA-DP4 positive, in line with the reported high 419 
frequency of this allele (33). Therefore, it was not surprising that we could frequently detect 420 
HLA-DP restricted cells (Supplementary Table S1A). 421 
Besides studying cytokine production by the Mage-A3243-258 peptide-specific CD4 T-cells, we 422 
used highly purified tetramers (42) produced with this peptide and recombinant HLA-DP*0401 423 
protein, allowing to identify two CD4 T-cell populations with different tetramer staining 424 
intensities. Interestingly, they represented two dominant clonotypes with different cytokine 425 
profiles. It is worthwhile to note that the differences in tetramer staining intensity remained 426 
stable over time, and did not reflect different levels of TCR downregulation. On the contrary, the 427 
low tetramer staining cells expressed even higher TCR levels, which could be due to lower 428 
triggering and thus less TCR downregulation. This may possibly be associated with lower TCR 429 
affinity, and/or different fine specificity. Indeed, it has been shown that a given peptide can make 430 
different configurations on a particular MHC class II protein, resulting in different epitopes 431 
recognized by different TCR (fine) specificities (43-45). In this regard, our observations are 432 
based solely on a single patient. Generalization would require more extensive studies which are 433 
beyond the scope of this clinical trial. 434 
In conclusion, the vaccinations of this study induced tumor-specific T-cells in the majority of 435 
patients. CD4 T-cell responses were very satisfactory. CD8 T-cell responses were less frequent, 436 
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but still comparable to vaccines formulated with TLR2 ligands (46) or TLR4 ligands (24), and 437 
more frequent than with protein vaccines (20). The CD8 T-cell responses were however less 438 
frequent and less strong as compared to vaccines with short peptides, IFA and CpG-B, 439 
representing the currently most potent synthetic vaccine formulation for the induction of human 440 
CD8 T-cell responses (32). Future vaccine strategies may profit from combinations with multiple 441 
TLR/innate immune stimulators, potentially capable of mimicking immune responses to viruses 442 
that can generate more robust and long lasting T-cell responses (47) (and manuscript in 443 
preparation). Thus, beside multiple antigens (possibly also including mutated antigens; (48), 444 
future vaccines may also require multiple immune “adjuvants”. In such scenarios, the role of 445 
IMP321 and its activatory effects on APCs (9) remains to be determined. 446 
Although the clinical results were relatively favorable, they cannot be firmly interpreted as this is 447 
a phase I study and has not been designed to determine clinical efficacy. Before designing 448 
larger phase III studies with clinical endpoints, it will be useful to further define the clinical role of 449 
IMP321, particularly with respect to vaccine component combinations as mentioned above. 450 
Carefully performed phase I/II studies may evaluate candidate treatment combinations, based 451 
on their capabilities of sound systemic T-cell activation and also overcoming immune 452 
suppression and T-cell exhaustion in the tumor microenvironment (49). Triggering HLA class II 453 
with IMP321 may have effects that are complementary or even synergistic to TLR stimulation 454 
(9). Furthermore, although we did not combine with checkpoint blockade (e.g. anti-CTLA-4 or 455 
anti-PD1/PD-L1 antibodies), there is a sound rational for doing so, as the antigen-specific nature 456 
of vaccines enhances treatment specificity and thus may increase the efficacy/toxicity ratio of 457 
checkpoint blockade (8, 49). 458 
 459 
  460 
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Figure and Table legends 605 
Fig. 1: Overview of specific T-cell frequencies 606 
CD8 purified cells from vaccinated melanoma patients were stimulated with peptide pools for 12 607 
days, harvested and stained with combinatorial tetramers, as described in Materials and 608 
Methods. The detection limit was set at 0.1%. The left part of panel (A) shows numbers of 609 
patients with detectable specific cells, considering patients that had at least one culture well with 610 
detectable cells. The right part shows the culture wells with detectable specific cells of the 611 
numbers of stimulated wells, in patients with positive cultures. Percentages are indicated with 612 
bars, accompanied by the numbers of patients and wells, respectively. (B) Detected specific T-613 
cells were divided in 3 categories depending on frequency : > 10%, between 1% to 10%, and 614 
between 0.1% to 1%. Graph shows the distribution of frequency found in positive wells for each 615 
specificity in at least two patients. The numbers of patients and wells analyzed in this graph are 616 
listed in the panel A. 617 
Fig. 2: Frequencies of Melan-A and NY-ESO-1-specific CD8 T-cells after IVS, before 618 
and after vaccination 619 
Blood samples of vaccinated melanoma patients were collected before vaccination (C0), after 1, 620 
2, and 3 cycles of vaccination (C1, C2, and C3 respectively), and for some patients, 6 months 621 
after the last vaccine (FU: follow up). PBMC were isolated, CD8 T-cells purified and stimulated 622 
with peptide pools for 12 days (IVS), harvested and stained with combinatorial tetramers, as 623 
described in Materials and Methods. (A) and (B) Graphs show the mean of the positive wells in 624 
positive patients, corresponding to a frequency above detection limit (> 0.1%). (B) Lines link 625 
samples from the same patient. (C) and (D) Post-V corresponds to the mean of all positive wells 626 
analyzed after vaccination, from C1 to FU. (D) Analysis of the frequency changes after 627 
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excluding the 3 patients who showed high frequencies already at baseline (C0 > 15%; patients 628 
Lau 1366, Lau 616 and Lau 1438). The numbers of patients and wells analyzed are listed in Fig. 629 
1A. 630 
Fig. 3: Frequencies of circulating Melan-A-specific CD8 T-cells 631 
Melan-A-specific CD8 T-cells were measured directly, without any culture step, after CD8 632 
enrichment, in blood samples of vaccinated melanoma patients. (A) Frequency of tetramer 633 
positive cells among the CD8+ T-cells, in Log10 scale, before vaccination (C0), and the 634 
maximum frequency measured after vaccination (in C1, C2, C3 or FU; MAX post-V). The cross 635 
represents a frequency below the detection limit of 0.01%, drawn arbitrarily at 0.005%. The 636 
detailed data are shown in Supplementary Table S3. (B) Correlation between direct ex vivo 637 
measurements (in panel A) and those after IVS (Fig. 2), from the same blood sample, when 638 
both measures were above the detection limits. Axes show calculated Log10 of the frequency. 639 
The curve shows linear regression. 640 
Fig. 4: Quantification of Mage-A3243-258-specific CD4 T-cells 641 
CD4 T-cells from vaccinated melanoma patients were purified and stimulated with Mage-A3243-642 
258 peptide for 10 days (IVS), as described in Materials and Methods. C0, C1, C2, C3 and FU 643 
correspond to the number of vaccination cycles administrated. (A) and (B) Frequency of 644 
intracellular IFN-γ and TNF-α producing T-cells after 4 hours of peptide challenge. (C) Cultures 645 
from 6 patients (n = 6; Lau 1187, Lau 1268, Lau 1314, Lau 1342, Lau 1366, and Lau 1409) 646 
were challenged with the Mage-A3243-258 peptide for 5 hours, in presence of blocking anti-HLA-647 
DP, anti-HLA-DQ or anti-HLA-DR antibodies. “Fold increase” was determined by background 648 
subtraction and normalization in reference to the condition stimulated with peptide alone. (D) 649 
Quantification of Mage-A3/DP4 tetramer positive cells among total CD4+ T-cells in the HLA-650 
DP4 positive patients and patient Lau616 (cross symbol) (n =14). 651 
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Fig. 5: Mage-A3/DP4-specific CD4 T-cells from patient Lau 1187 showing two 652 
phenotypes with tetramer-high and tetramer-low staining 653 
CD4 T-cells from Lau 1187 were purified and stimulated with Mage-A3243-258 peptide (IVS), as 654 
described in Materials and Methods. Blood sample collected after 3 vaccinations showed 2 655 
distinct tetramer positive populations. Tetramer-high (High) and tetramer-low (Low) stained cells 656 
were sorted separately, and cloned. (A) FACS dot plots of the tetramer staining at the time 657 
points C0 (considered as background) and C1 (before sorting). (B) The clones were phenotyped 658 
to determine the expression levels of tetramer, TCR and CD4, in separate tubes. (C) 659 
Intracellular cytokine production of tetramer-high and tetramer-low clones after 6 hours of 660 
stimulation. (D) Polyfunctionality (co-expression of cytokines: TNF-α, IFN-γ, IL-2 and IL-13) of 661 
tetramer-high and tetramer-low clones in response to 5 µg/mL Mage-A4243-258 peptide. Colors of 662 
the pie arcs depict the expression of individual cytokines, while the patterns of the pie depict the 663 
number of co-expressed cytokines from zero (white) to four cytokines (black) 664 
Table 1: Summary of the immune responses induced by vaccination in melanoma 665 
patients 666 
The table summarizes specific CD8 T-cell responses obtained after IVS (Fig. 2), Melan-A-667 
specific CD8 T-cell responses quantified ex vivo (Fig. 3A and Supplementary Table S3) and 668 
Mage-A3-specific CD4 T-cell responses (Fig. 4) with an increase of 2-fold or more (+) compared 669 
to baseline (C0). 670 
Supplementary Fig. S1: Gating strategy used to determine the T-cell frequencies with the 671 
combinatorial tetramer staining. 672 
Supplementary Fig. S2: Specific CD8 T-cell frequencies before and after each cycle of 673 
vaccination 674 
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To complete the results depicted in Fig. 2, we show here the frequencies found for (A) virus and 675 
(B) tumor-specific T-cells in PBMC collected before the first vaccine (C0), and one week after 676 
the third vaccination of each cycle (C1, C2, C3). Graphs show the mean of the positive wells in 677 
positive patients, corresponding to frequencies above the detection limit (> 0.1%). Lines link 678 
samples from the same patient. Post-V corresponds to the mean of all positive wells analyzed 679 
after vaccination, from C1 to FU. The numbers of patients and wells analyzed are listed in Fig. 680 
1A. 681 
Supplementary Table S1: Patients’ characteristics and adverse events list 682 
(A) Detailed information on melanoma patients. (B) List of adverse events encountered during 683 
the study with an incidence of > 5 according to their CTCAE severity scale and their relationship 684 
to the study treatment. 685 
Supplementary Table S2: Combinatorial tetramer staining for HLA-A2 restricted CD8 T-686 
cells 687 
List of tetramers used in combinatorial tetramer staining. All these tetramers were HLA-A2 688 
tetramers, produced with 9-mers or 10-mers, and conjugated with a single or combination of 689 
different indicated fluorochromes. 690 
Supplementary Table S3: Maximum frequency of the antigen-specific T-cells identified 691 
in the IVS cultures 692 
The figure lists the detailed data that is summarized in Fig. 1A, showing all individual maximum 693 
specific T-cell frequencies found for each patient in Fig. 2A, 2B and Supplementary Fig. S2, 694 
upper panel (detected at a frequency of > 0.1%; -: not detected in the patient). 695 
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Supplementary Table S4: Direct ex vivo analysis of circulating Melan-A-specific CD8 T-696 
cell frequencies 697 
The data show the detailed results that were summarized for the generation of Fig. 3. The 698 
frequencies indicate the percentage of A2/Melan-A tetramer+ cells of total CD8+ T-cells. 699 












Supplementary text : 
Supplementary Materials and Methods 
 
Vaccination 
The clinical-grade peptides used in the vaccines were: Melan-A26-35 native EAAGIGILTV or analog (A27L) 
ELAGIGILTV, NY-ESO-1157-165 SLLMWITQC, Mage-A3112-120 KVAELVHFL, NA17 VLPDVFIRC, all representing 
known class I HLA-A2 peptides; and Mage-A3243-258 KKLLTQHFVQENYLEY, containing a class II HLA-DP4 
epitope. In the first cycle, patients received 10µg Mage-A3/A2, NA17 and NY-ESO-1 peptides, and 100µg Melan-A 
native peptide. In the second and the third cycles, the peptide dose was increased to 100µg each, and the Melan-
A analog peptide was used in place of the native. Mage-A3/DP4 peptide was injected at the dose of 200µg during 
all cycles. Vaccines of the third cycle were prepared without Montanide. Blood samples were collected before the 
first vaccine (C0), one week after the third vaccination of each cycle (C1, C2, C3), and 6 months after the end of 
the third cycle (follow up : FU) for some patients.  
 
In Vitro Stimulation (IVS) of T-cells with specific peptides 
Cryopreserved PBMCs were thawed, and CD8+ T-cells or CD4+ T-cells were enriched using MACS technology 
(Miltenyi Biotec). The negative fraction of cells were loaded with laboratory-grade peptides (listed in 
Supplementary Table S2A), irradiated (30 Gray) and used as antigen-presenting cells to stimulate peptide-specific 
T-cells. 100.000 cells per well of each fraction were plated in 96 well U-bottom plates, or 1 million per well of 24 
well plates. Cultured cells were maintained 10 or 12 days at 37°C in RPMI1640 medium supplemented with 8% 
human serum. CD4+ T-cells were stimulated in presence of 20 U/ml IL-2 from day 0; CD8+ T-cells were 
supplemented with IL-2 (100 U/ml) starting after one day of culture.  
 
Flow cytometry: quantification of specific T-cells by tetramer staining 
Freshly thawed cells or cultured cells were stained using similar protocols. As a first step, single tetramer staining 
or combinatorial tetramer staining (TCMetrix, Lausanne, Switzerland) was performed. Cells were incubated 45 
minutes at room temperature with class I tetramers (combinatorial tetramers or tetramer Melan-A-PE) or 60 
minutes at 37°C with class II tetramer (tetramer Mage-A3/DP4-PE). The combinatorial tetramers are listed in 
Supplementary Table S2A. One or three washing steps (for single or combinatorial staining, respectively) were 
performed in FACS buffer (PBS supplemented with 5mM EDTA, 0.2% azide and 0.2% BSA). Surface staining was 
performed to identify CD4 and CD8 T-cells at 4°C for 20 minutes using CD4-FITC (clone 13B8.2), CD8-PerCP-
Cy5.5 (clone SK1), CD3-APC (clone UCHT1), CD4-APC-H7 (clone SK3) and/or CD3-Alexa Fluor 700 (clone 
HIT3a). Finally, LIVE/DEAD-Fixable-Aqua (Invitrogen) or DAPI was used as a dead cell exclusion marker. Data 
were acquired on a Gallios Flow Cytometer (Beckman Coulter) and analyzed using FlowJo 7.6.5 software 
(TreeStar).  
 
Mage-A3-specific CD4 T-cell clones, cell sorting and stimulation 
A blood sample from patient Lau1187 (collected after 3 vaccines; C1) was stimulated with Mage-A3243-258 peptide 
for 16 days, as described above in IVS section. Cells were harvested and stained with Mage-A3/DP4 tetramer 
(TCMetrix, Lausanne, Switzerland) and CD4-APC-H7 antibody as described in tetramer staining section. CD4+ 
tetramer-low and CD4+ tetramer-high cells were separately sorted with a BD FACS Aria cell sorter, and cultured in 
Terasaki plates at 0.5 cell per well with 10.000 feeder cells (mix of irradiated PBMC from 2 healthy donors) per 
well, 150 U/mL IL-2, 1 µg/mL PHA. After at least 1 week in culture, growing wells were transferred in 96 well U-
bottom plates for expansion. The specificity of each clone was checked by tetramer staining analyzed by flow 
cytometry (BD FACS Array). Clones were restimulated, when necessary, with feeder cells, IL-2 and PHA. 12 days 
after stimulation, clones were stained with tetramer Mage-A3/DP4-PE, or CD4-PE (clone 13B8.2), or TCR pan 
alpha/beta-PE (clone IP26A) antibodies to phenotype the cells. DAPI was used to exclude dead cells. In parallel, 
clones were stimulated with 0,5 and 5 µg/mL Mage-A3243-258 peptide in presence of Brefeldin A 10µg/mL for 6 
hours. Intracellular Cytokine Staining (ICS) was done as described below. 
 
ICS, assessed by flow cytometry 
The quantification of cytokine amounts specifically produced by T-cells in response to a peptide was assessed by 
flow cytometry using intracellular staining. T-cells were stimulated for 4 to 6 hours with or without 1 or several 
peptides at 1 µM each, in RPMI1640 medium supplemented with 10% FCS, plus 10µg/ml Brefeldin A, at 37°C. 
PMA/Ionomycin stimulation was used as positive control. After stimulation, surface and dead cell staining were 
performed as described in previous section, using the following antibodies: CD3-PE (clone UCHT1), CD8-PerCP-
Cy5.5 (clone SK1), and CD4-Pacific Blue (clone 13B8.2). Stained cells were then fixed with fixation buffer (PBS, 
1% formaldehyde, 2% glucose, 5mM azide), permeabilised with 0.1% saponin in FACS buffer, and incubated with 
anti-cytokine antibodies (IL-2-FITC, clone MQ1-17H12 ; IFN-γ-PE-Cy7, clone 4S.B3 ; IL-13-APC, clone JES10-
5A2 ; and TNF-α-Alexa Fluor 700, clone MAb11), for 20 minutes at room temperature, in the dark. Analysis of 
cytokine co-expression was done with SPICE software version 5.2. 
 
